Skip to main content

Home/ Nutrition/ Group items tagged cvd supplementation prevention

Rss Feed Group items tagged

Matti Narkia

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocar... - 0 views

  •  
    Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
    [No authors listed]
    Lancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet 2001 Feb 24;357(9256):642. Lancet. 2007 Jan 13;369(9556):106.
    PMID: 10465168

    Interpretation
    Dietary supplementation with n-3 PUFA led to a clinically important and satistically significant benefit. Vitamin E had no benefit. Its effects on fatal cardiovascular events require further exploration
Matti Narkia

Benefits of Vitamin D Supplementation - Journal of American Physicians and Surgeons Vol... - 0 views

  •  
    Benefits of Vitamin D Supplementation
    Joel M. Kauffman, Ph.D.
    Journal of American Physicians and Surgeons
    Volume 14 Number 2 - Summer 2009

    Clinical trials show that vitamin D supplementation at higher
    levels than previously recommended is beneficial for many
    conditions. It decreases the frequency of falls and fractures, helps
    prevent cardiovascular disease, and reduces symptoms of colds or
    influenza. Benefits are also seen in diabetes mellitus, multiple
    sclerosis, Crohn disease, pain, depression, and possibly autism.
    Sunlight does not cause an overdose of vitamin D production,
    and toxicity from supplementation is rare. Dose recommendations
    are increasing, but appear to be lagging the favorable trial results. A
    number of common drugs deplete vitamin D levels, and others may
    limit its biosynthesis from sunlight.
    People with adequate levels from sun exposure will not benefit
    from supplementation. While dietary intake is helpful,
    supplementation is better able to raise serum 25-hydroxyvitamin D ,
    the major circulating metabolite, to the level now thought adequate,
    30-50 ng/mL.
    Where there is inadequate daily sun exposure, oral doses of
    1,000-2,000 IU/d are now considered routine, with much higher
    doses (up to 50,000 IU) for rapid repletion now considered safe.
Matti Narkia

Massive vitamin-D/omega-3 trial in the works - theheart.org - 0 views

  •  
    "June 29, 2009 | Shelley Wood

    Boston, MA - A massive, National Institutes of Health-sponsored study looking at whether vitamin-D and/or omega-3 fatty-acid supplementation can reduce the risk of developing heart disease, stroke, or cancer will get under way in January 2010, according to a website for the study. Drs JoAnn Manson and Julie Buring (Harvard Medical School/ Brigham and Women's Hospital, Boston, MA) will head up the Vitamin D and Omega-3 Trial (VITAL).

    The study is aiming to enroll 20 000 men and women, one-quarter of whom will be black. According to a Brigham and Women's Hospital press release, the study is intentionally aiming to illuminate a potential racial and ethnic disparity hypothesized to be linked to vitamin D [1]. "African Americans have a higher risk of vitamin-D deficiency as well as a greater frequency of diabetes, hypertension, and certain types of cancer," a press release notes. For VITAL, women need to be over age 65 to enter the study; men need to be over age 60.

    Study participants will be randomized to one of four groups: daily vitamin D (2000 IU) and fish oil (1 g); daily vitamin D and fish-oil placebo; daily vitamin-D placebo and fish oil; or daily vitamin-D placebo and fish-oil placebo. The trial will run for five years and is expected to cost US $20 million."
Matti Narkia

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated... - 0 views

  •  
    Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
    Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.
    Circ J. 2009 Jul;73(7):1283-90. Epub 2009 May 8.
    PMID: 19423946

    Conclusions: EPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and
    should be added to conventional treatment.
Matti Narkia

Omega 3 fatty acids from fish oil, HF treatment, and prevention - 0 views

  •  
    "In one room on the last day of the conference, four invited faculty members meticulously made the case for an already-available substance as an example of the kind of agent the others were looking for. Their message: omega-3 polyunsaturated fatty acids (PUFAs), usually derived from fish oil, garner far less attention as a heart-failure therapy than they deserve, given the wealth of laboratory and clinical evidence supporting a treatment effect."
Matti Narkia

n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefi... - 0 views

  •  
    Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. \nn-3 Fatty acids from fish or fish-oil supplements, but not \nalpha-linolenic acid, benefit cardiovascular disease outcomes in \nprimary- and secondary-prevention studies: a systematic review. \nAm J Clin Nutr. 2006 Jul;84(1):5-17. Review. \nPMID: 16825676
Matti Narkia

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocar... - 0 views

  •  
    Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.\nLancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet 2001 Feb 24;357(9256):642. Lancet. 2007 Jan 13;369(9556):106.\nPMID: 10465168
1 - 8 of 8
Showing 20 items per page